The goal of this study is to evaluate whether hormonal medications (such as contraceptive pill, patch, injectable progestins and hormonal intra-uterine device) have similar efficacy at managing heavy menstrual bleeding in adolescents with a bleeding disorder compared to those without. We also aim to assess the quality of life and hemoglobin and iron levels in this population.
Adolescents with heavy menstrual bleeding and willing to start a hormonal medication to reduce menstrual flow are included. At baseline and during the study period, questionnaires and blood tests are performed. Adolescents with a bleeding disorder are compared to those without. Follow-up is 1 year.
Study Type
OBSERVATIONAL
Enrollment
163
Geneva University Hospitals
Geneva, Switzerland
RECRUITINGPercentage of reduction in menstrual blood loss
Using PBAC (pictorial blood loss assessment chart)
Time frame: 6 months after hormonal medication initiation
Percentage of reduction in menstrual blood loss
Using PBAC
Time frame: 3 months following hormonal medication initiation
Percentage of reduction in menstrual blood loss
Using PBAC
Time frame: 12 months after hormonal medication initiation
Quality of life
QoL (measured by the Pediatric Quality of Life Inventory (PedsQL) for adolescents (13-18 years old) or young adults (19-25 years old)) ; range 0-100 with higher scores representing better quality of life.
Time frame: at baseline, 3 months, 6 months and 12 months
Hemoglobin and ferritin levels changes
Blood samples to measure hemoglobin and ferritin
Time frame: at baseline, 6 months and 12 months
Changes in thrombin generation markers
Blood sample
Time frame: at baseline and 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.